Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Aquestive Therapeutics heads into its November earnings with short interest near a multi-year peak, borrow availability back at its floor, and options positioning edging more defensive, a combination that defines the tension heading into the next catalyst.
Short sellers have been steadily adding pressure throughout the past six weeks. Short interest climbed to 23.5% of the free float by October 13, up roughly a third over the past month. The week-on-week gain of 4.5% brings the position to its highest level in the current run, with FINRA's official fortnightly data putting the equivalent figure at 28.7 million shares and 13 days to cover. That is not a fringe short book; it is a structurally large bet against a small-cap pharma name trading at $4.67.
The lending market is where the story gets sharper. Availability has collapsed back to 1.7% of the shares already borrowed, meaning for every 58 shares lent out there is barely one left in the pool. That is near fully tapped. For context, the 52-week minimum availability was 0.06%, reached during the tightest window of the past year, and the current reading is trending back toward that level after a brief loosening mid-week. The cost to borrow has eased from recent highs, running at 1.36% annually, down from 1.77% a week ago, suggesting the borrow rate itself is not yet screaming distress even as the supply shrinks. Options are tilting modestly more cautious: the put/call ratio of 0.61 is roughly one standard deviation above its 20-day average of 0.55, a mild defensive lean rather than a panic hedge. The 52-week low on the PCR was 0.12, and the high was 1.35, so the current level sits well inside those extremes.
The Street remains constructive on paper, though the analyst data is somewhat dated. Coverage carries a consensus buy rating, with a mean price target around $9.33 against the current $4.67 price. The most recent reiteration from HC Wainwright in late August held its $10 target, and earlier raises from Piper Sandler, JMP Securities, and Oppenheimer over the past year all pointed targets higher. The bull case rests on Anaphylm, the no-needle epinephrine candidate whose FDA review cleared an advisory committee hurdle that had been a concern, prompting the stock's 44% spike that is now partly faded. The bear case is straightforward: pipeline execution risk on AQST-109, potential erosion in licensed product revenues, and balance sheet pressure that may require further capital raises. Factor scores tell an interesting split story. EPS momentum ranks in the 90th percentile over 90 days and the 70th over 30, and the company has historically beaten estimates at an 86th-percentile rate. But the ORTEX short score sits at 81.7, placing it in the 2nd percentile of the universe on that metric, a signal that the aggregate of short-side indicators is firmly negative.
Ownership adds another layer of interest this week. Two new Schedule 13G filings appeared on October 7. Edward Bass filed a fresh 13G disclosing a 7.5% stake of 9.4 million shares, while Thru Line L.P. entered the register with 7.9 million shares representing 6.3%. Separately, BRATTON DOUGLAS K filed a 13G/A showing their stake had dropped sharply from 11.1% to 0.6%, a material reduction that freed up a large block in the market. BlackRock also amended its 13G/A earlier in July, lifting its disclosed stake from 5.3% to 6.4%. These are event-driven disclosures around the 5% threshold, and positions can fall below that level without a subsequent filing, so they represent the picture as last disclosed rather than a live read. Still, two fresh large passive entries on the same day is notable in a stock this size. Wikipedia attention data flagged a z-score of 5.2 for retail interest as of late September, the highest reading in the dataset's recent range, consistent with the post-FDA-news attention the stock attracted.
Recent earnings reactions have been mixed in direction but contained in magnitude. The August 2026 print moved the stock down roughly 3.6% on day one before recovering 4% over the following week. A prior event in August produced a smaller initial decline with a similarly muted five-day recovery. The standout in the history is an August 7, 2026 result that produced a 9.4% single-day gain and an 8.4% five-day follow-through. The next print is scheduled for November 4, 21 days away.
With availability near its floor, short interest at a cyclical high, and a fresh cluster of large ownership disclosures reshaping the register, the key question heading into November 4 is whether any progress on Anaphylm's regulatory timeline or a balance sheet update shifts the calculus for either side of a trade that has grown notably one-sided in recent weeks.
See the live data behind this article on ORTEX.
Open AQST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
